Results 121 to 130 of about 1,129 (187)

Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults. [PDF]

Eur J Clin Pharmacol, 2016
Webb NJ, Wells T, Tsai M, Zhao Z, Juhasz A, Dudkowski C.   +5 more
europepmc   +1 more source

Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry [PDF]

AD Bremner, AK Gitt, AM Sharma, Anselm K. Gitt, AR De Caterina, DW Laight, EC Li, F Zannad, Felix Mahfoud, G Bonner, G Mancia, G Reboldi, GB Appel, GL Bakris, Hartmut Buhck, J Roy, JD Jones, Jochen Senges, LP Hasvold, Martina Ehmen, Peter Baumgart, Peter Bramlage, PM Kearney, R Petrella, RE Schmieder, Roland E. Schmieder, S Bezalel, S Lewington, S Yusuf, S Yusuf, Sebastian A. Potthoff, Taoufik Ouarrak, TW Kurtz, V Barrios, VR Anderson   +34 more
core   +1 more source

Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension. [PDF]

J Clin Hypertens (Greenwich), 2015
Kipnes MS, Handley A, Lloyd E, Barger B, Roberts A.   +4 more
europepmc   +1 more source

Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. [PDF]

Clin Exp Hypertens, 2016
Handley A, Lloyd E, Roberts A, Barger B.
europepmc   +1 more source

Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. [PDF]

J Hypertens, 2016
White WB, Cuadra RH, Lloyd E, Bakris GL, Kupfer S.   +4 more
europepmc   +1 more source

FDA Drug Repurposing Uncovers Modulators of Dopamine D₂ Receptor Localization via Disruption of the NCS-1 Interaction. [PDF]

J Med Chem
Muñoz-Reyes D, Aguado L, Arroyo-Urea S, Requena C, Pérez-Suárez S, Sánchez-Yepes S, Argerich J, Miró-Rodríguez C, Ulzurrun E, Rodríguez-Martín E, García-Nafría J, Campillo NE, Mansilla A, Sánchez-Barrena MJ.   +13 more
europepmc   +1 more source

The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure. [PDF]

J Clin Hypertens (Greenwich), 2017
Perez A, Cao C.
europepmc   +1 more source

Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry. [PDF]

J Clin Hypertens (Greenwich), 2015
Schmieder RE, Potthoff SA, Bramlage P, Baumgart P, Mahfoud F, Buhck H, Ouarrak T, Ehmen M, Senges J, Gitt AK, EARLY Registry Group.   +10 more
europepmc   +1 more source

New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. [PDF]

Integr Blood Press Control, 2012
Volpe M, Savoia C.
europepmc   +1 more source

Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. [PDF]

J Clin Hypertens (Greenwich), 2012
Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, Roberts A, Kupfer S.   +7 more
europepmc   +1 more source